The acquisition will add to Isto Biologics’ portfolio of orthopedic grafts and bring TheraCell’s patented TheraFuze DBF technology to Isto’s Influx product line. Isto Biologics focuses on bone regeneration and cell-based therapies for orthopedics.
Isto Biologics is backed by private equity firm Thompson Street Capital Partners.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.